offline
Novartis (NVS) Q3 Earnings & Sales Beat Estimates, Up Y/Y
Swiss pharma Novartis AG’s NVS earnings and sales beat estimates in the third quarter of 2019. The company also updated its sales guidance and expects annual sales toward the high end of its previous forecast.
Third-quarter 2019 core earnings (excluding one-time charges) of $1.41 per share beat the Zacks Consensus Estimate of $1.31 and increased from $1.22 reported in the year-ago quarter.
Revenues rose 10% year over year to $12.2 billion and beat the Zacks Consensus Estimate of $11.6 billion, driven by Cosentyx, Entresto, Zolgensma and the Xiidra acquisition.
...
https://finance.yahoo.com/news/novartis-...02950.html
![[Bild: NVSc1dl1332.png]](https://finviz.com/publish/102219/NVSc1dl1332.png)
Swiss pharma Novartis AG’s NVS earnings and sales beat estimates in the third quarter of 2019. The company also updated its sales guidance and expects annual sales toward the high end of its previous forecast.
Third-quarter 2019 core earnings (excluding one-time charges) of $1.41 per share beat the Zacks Consensus Estimate of $1.31 and increased from $1.22 reported in the year-ago quarter.
Revenues rose 10% year over year to $12.2 billion and beat the Zacks Consensus Estimate of $11.6 billion, driven by Cosentyx, Entresto, Zolgensma and the Xiidra acquisition.
...
https://finance.yahoo.com/news/novartis-...02950.html
__________________
